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Abstract
MBD2 is a subunit of the NuRD complex that is postulated to mediate gene repression via recruitment of the complex to
methylated DNA. In this study we adopted an MBD2 tagging-approach to study its genome wide binding characteristics.
We show that in vivo MBD2 is mainly recruited to CpG island promoters that are highly methylated. Interestingly, MBD2
binds around 1 kb downstream of the transcription start site of a subset of ,400 CpG island promoters that are
characterized by the presence of active histone marks, RNA polymerase II (Pol2) and low to medium gene expression levels
and H3K36me3 deposition. These tagged-MBD2 binding sites in MCF-7 show increased methylation in a cohort of primary
breast cancers but not in normal breast samples, suggesting a putative role for MBD2 in breast cancer.
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Introduction
DNA methylation is the covalent addition of a methyl group to
the cytosine of a CpG dinucleotide and represents an important
epigenetic mechanism involved in several biological processes like
X-inactivation [1], differentiation [2], genomic imprinting [3] and
cancer [4].
Around 70% of the CpG dinucleotides (CpGs) in the
mammalian genome are methylated [5] except for CpG islands
(CGIs), regions of high CpG density, that are usually unmethy-
lated [6]. However, CGIs promoters are not always unmethylated
and can acquire methylation during differentiation [7] or they can
be aberrantly methylated in cancer [8]. Methylation of promoter
CpG-islands is correlated to transcriptional repression [9] whereas
recent evidences show genome-body methylation being mainly
associated with transcriptional activity [10,11] [12].
It has been proposed that one of the mechanisms of
transcriptional repression mediated by CpGs methylation involves
binding of methyl-CpG-binding proteins (MBPs) to the methylated
cytosine and recruitment of a co-repressor complex [13]. MBPs
are divided in three different families: MBD (methyl binding
domain), Kaiso and SRA domain proteins [14]. The MBD family
includes MeCP2, MBD1, MBD2 and MBD4 that can bind
methylated DNA via the Methyl-CpG Binding Domain (MBD)
while three other members of this family namely MBD3, MBD5
and MBD6 do not bind methylated DNA [15].
MBD2 is a subunit of the Mi2-NuRD complex that was
previously shown to mediate gene repression via recruitment of the
complex to methylated promoters [16,17]. Since promoter hyper-
methylation is a well-known hallmark of cancer, several studies
linked MBD2 function to epigenetic regulation of genes critical
during carcinogenesis [18,19], however, most of these studies
looked at a limited number of target genes. Recent studies
challenged the model of MBD2 as a predominantly promoter-
proximal repressor suggesting that binding could also regulate
activity of target genes [20].
Although it has been widely shown that MBD2 selectively binds
methylated DNA in vitro [21,22] the proof that this also occurs in
vivo was only recently provided by genome wide binding of MBD2
and other family members by comprehensive chromatin immu-
noprecipitation (ChIP) sequencing [23,24]. Genome wide map-
ping of MBD2 binding in mouse embryonic stem cells showed that
in vivo binding predominantly occurs at highly methylated, CpG
dense regions, although a subset of binding sites was detected at
active unmethylated promoters. Another recent study in HeLa
cells showed that MBD2 mainly binds promoters of inactive genes
and extrapolated this observation to imply that MBD2 acts as
repressor at those regions [23].
To gain further insights into the function of and epigenetic
regulation by MBD2 we generated a tagged version of the protein
and stably expressed it in the MCF-7 cell line. We mapped
genome wide binding of MBD2 by ChIP sequencing (ChIP-seq)
and together with base resolution whole genome bisulfite
sequencing (WGBS) we determined the methylation content and
the possible role of methylation density at MBD2 enriched regions.
We also categorized the epigenetic make up of MBD2 binding sites
taking advantage of a large body of ChIP-seq data and detected
MBD2 at a subset of lowly active promoters. Regions bound by
MBD2 in MCF-7 show overall increased methylation levels in a
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large set of primary breast cancer samples but not in a model of
non-cancer human mammary epithelial cells.
Results and Discussion
Tagged MBD2 incorporates into native NuRD-complex
In order to study the genome wide binding of MBD2 we
generated a tagged version (hereafter referred as TTE-MBD2,
Fig 1A) stably expressed in MCF-7 as at the initiation of this study,
the available commercial MBD2 antibodies were of low quality
and/or not suited for ChIP-seq. The epitope tag (TY1-TY1-ER)
had already been successfully used for IP and ChIP applications
[25] and was placed at the N-terminus of the protein. TTE-MBD2
expressed in MCF-7 cells is specifically recognized by the Ty1
antibody (Fig1B left panel), that does not detect the endogenous
protein in wild type MCF-7 cells (WT). Western blot analysis with
an MBD2-specific antibody showed that the tagged protein is
expressed considerably higher as compared to endogenous MBD2
levels (Fig 1B, right panel).
Next we performed large-scale Ty1 immunoprecipitation on
both TTE-MBD2 and WT cells followed by mass spectrometry
analysis in order to determine whether the exogenous TTE-MBD2
is assembled into a NuRD complex. Results from triplicate pull-
downs were analyzed with MaxQuant and label-free quantitation
(LFQ) intensities were used to determine statistically enriched
MBD2 interactors as previously described [26]. Amongst the 25
most significantly enriched interactors, the well-known MBD2-
NuRD complex components CHD3/4, GATAD2A/B, MTA1/
2/3, HDAC1/2 and CDK2AP1 (DOC-1) are co-precipitated
(Fig1 C, black squares). We further detected RBBP4 but not
RBAP46 (RBBP7) which share 90% sequence homology. A list
with the specific interactors is reported (Table 1) and a full list of
all identified proteins is also available (Table S1). Interestingly,
among the specific interactors we could detect several zinc-finger
and other DNA binding proteins. Our findings indicate that the
tagged MBD2 is at least in part incorporated in a NuRD-like
complex [21] and thus that the tag unlikely interferes with the
composition of the complex.
MBD2 is preferentially associated with CGI-promoters
In order to assess genome wide binding of MBD2 we isolated
chromatin from TTE-MBD2 and WT MCF-7 cells, and
performed ChIP sequencing. To preserve protein-protein interac-
tions we stabilized the MBD2-NuRD complex on chromatin by
applying a double crosslinking method [27]. Cells were first
treated with 1.5 mM disuccinimidil glutarate (DSG) before
applying the standard formaldehyde fixation. Along with Ty1-
tag antibody (Fig S1), we also used antibodies against MBD2 that
became commercially available in the course of the study. ChIP-
seq using the Ty1 antibody on WT MCF-7 cells was performed as
a negative control (data not shown) to correct for possible antibody
cross-reactivity. One of the commercial MBD2 antibodies showed
the highest signal over background data compared to Ty1 ChIP
Figure 1. Generation of a tagged MBD2. a) Schematic presentation of tagging approach: double Ty1 and ER epitopes are inserted at the N-
terminal of human full length MBD2. b) Western blot on whole cell lysates from TTE-MBD2 MCF-7 and WT MCF-7. Antibodies against tag (Ty1) and
MBD2 are used. GAPDH is shown as loading control. c) Volcano plot showing results from Mass Spectrometric Analysis of immunoprecipitation
experiment. The x-axis shows the log of ratios between LFQ intensities in TTE-MBD2 against the control WT. The y-axis display 2log10 of the p-value
calculated by a permutation-based FDR-corrected t test. The black dots underline Mi2-NuRD complex components within the significantly enriched
interactors (grey dots).
doi:10.1371/journal.pone.0099603.g001
Genome-Wide Binding of MBD2 Prefers Highly Methylated Loci
PLOS ONE | www.plosone.org 2 June 2014 | Volume 9 | Issue 6 | e99603
and was subsequently used in the data analysis. MBD2 binding
sites were identified using MACS 2.0 [28] with a p-value of 10e6
resulting in 8349 peaks. A pile-up heatmap showing quantitation
of tags 5 kb up- and downstream the center of MBD2 binding sites
(Fig 2A left panel) revealed strong signal intensity, which is absent
in the input (Fig 2A middle panel). A biological replica of a MBD2
ChIP-seq experiment revealed high reproducibility of the data
(Fig 2A right panel). Specificity of the binding was validated by
ChIP-qPCR on TTE-MBD2 and wild type MCF-7 cells using the
MBD2 as well as Ty1 antibody (Fig S1). The MBD2 binding sites
with highest tag density were also enriched in Ty1 ChIP-seq using
TTE-MBD2 but not in WT MCF-7 cells (Fig S2).
The genomic distribution of MBD2 binding sites was deter-
mined in comparison to a random set of genomic regions with the
same average length, representative of the total genomic sequence
distribution (Fig 2B). Genomic features such as intron, intergenic,
exons and promoters were subsequently grouped accordingly to
their GC content (Fig 2C). Binding preferentially occurs at CpG
islands (CGIs) in particular at promoters and to a lower extent at
exons as previously reported [24]. Representative examples of
MBD2 binding are shown (Fig 2D). Strong binding is observed at
the CGI promoter of KDM2 gene as well as at the CGI exons of
MZF1, ZNF837 and ZNF497.
Methylation density plays a critical role in MBD2 binding
A large body of data strongly suggests that MBD2 specifically
binds to methylated DNA in vitro [16,21] but evidence for its
binding to methylated DNA in vivo was only recently obtained in
mouse embryonic stem cells [24]. Therefore, we assessed the DNA
methylation levels at MBD2 binding sites. Base pair resolution
whole genome bisulfite sequencing (WGBS) was performed on
MCF-7 cells as recently described [29]. Bisulfite conversion rate
was around 99.9% and 51.4 mean coverage of CpG dinucleotides.
The percentage of DNA methylation underneath MBD2 peaks
was determined and compared with methylation levels at a
random set of genomic regions matched for genomic distribution
of MBD2 binding sites. MBD2 binding was clearly enriched at
methylated genomic loci since more than 80% of the binding sites
had DNA methylation levels between 80-100% (Fig 3A), whereas
in the random set the level ranges from 10 to 90%. In order to
check the correlation between methyl-CpG density and MBD2
binding genome wide we binned the genome in 1 kb windows and
calculated MBD2 enrichment over input and methylation density
within each window. Methylation density was expressed as the
sum of methylated CpGs for each CpG dinucleotide normalized
by length. Next we ranked the windows according to their
methylation density (Fig 3B dashed line) and calculated MBD2
enrichment (green plot). A strong correlation between the two
variables was detected as previously observed in mouse ESCs [24].
Table 1. List of TTE-MBD2 specific interactors identified from Mass Spectrometry.
Gene names Protein names (-)Log t-test p value t-test Difference
MTA1 Metastasis-associated protein MTA1 8.32954 1.84248
ZNF512B Zinc finger protein 512B 8.03327 1.34558
CHD4 Chromodomain-helicase-DNA-binding protein 4 7.75574 2.20372
BCL11B B-cell lymphoma/leukemia 11B 7.58416 2.79627
CTBP2 C-terminal-binding protein 2 7.27166 2.11806
HDAC2 Histone deacetylase 2;Histone deacetylase 6.60528 2.09939
CUX1 Homeobox protein cut-like 1 6.17975 2.21916
GATAD2A Transcriptional repressor p66-alpha 6.14678 2.2355
MTA3 Metastasis-associated protein MTA3 6.1107 2.4135
TRPS1 Zinc finger transcription factor Trps1 6.04 3.19905
ZBTB7B Zinc finger and BTB domain-containing protein 7B 6.03263 3.31228
CDK2AP1 Cyclin-dependent kinase 2-associated protein 1 5.69484 2.27067
HDAC1 Histone deacetylase 1 5.64503 2.09078
ZNF219 Zinc finger protein 219 5.42088 2.24232
CHD3 Chromodomain-helicase-DNA-binding protein 3 5.37692 2.90386
CASZ1 Zinc finger protein castor homolog 1 5.03132 3.4185
RBBP4 Histone-binding protein RBBP4 4.97025 2.05424
BEND3 BEN domain-containing protein 3 4.75216 2.19638
PGBD3 PiggyBac transposable element-derived protein 3 4.70819 2.23163
GATAD2B Transcriptional repressor p66-beta 4.50829 3.32597
MECOM MDS1 and EVI1 complex locus protein EVI1 4.00392 2.05347
ZBTB10 Zinc finger and BTB domain-containing protein 10 3.53701 2.11845
C1QBP Complement component 1 Q subcomponent-binding protein 2.822 2.45405
PRR12 Proline-rich protein 12 2.51089 2.36333
25 most significantly enriched TTE-MBD2 interactors, identified after Ty1 immunoprecipitation on both TTE-MBD2 and WT cells followed by mass spectrometry analysis.
Results from triplicate pull-downs were analyzed with MaxQuant and label-free quantitation (LFQ) intensities were used to determine statistically enriched MBD2
interactors. Immunoprecipitation from wild type (WT) MCF-7 was used as a control.
doi:10.1371/journal.pone.0099603.t001
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Figure 3C shows representative examples; the red track displays
methyl-CpG density computed over 50 bp windows across the
genome. MBD2 peaks clearly coincided with increased methyla-
tion density as also exemplified for KCNN2, ZNF316, and
ASCL5.
A subset of MBD2 binding sites marks active CpG island
promoters
To further characterize MBD2 binding sites we determined the
epigenetic marks at the enriched loci, to gain insight into a
putative role of MBD2 in gene regulation. We performed RNA
polymerase II (Pol2), H2A.Zac and H3K4me3 ChIP-seq in MCF-
7 as well as strand-specific RNA-seq, while other data-sets were
retrieved from the ENCODE project. Histone marks and
transcription factors associated with active promoters (Pol2,
H2A.Zac, H3K4me3, H3K36me3, H3K27ac) as well as enhanc-
ers (H3K27ac, P300), repressive marks (H3K27me3, H3K9me3)
and methyl CpG (mCpG) levels were selected for this analysis.
Note that the epigenetic profiles were generated in wild type
MCF-7 cells, not in the line over-expressing TTE-MBD2.
For each dataset we calculated tag densities 5 kb up and
downstream of the center of the MBD2 binding sites and
performed k-means clustering to group the binding sites into
distinct clusters. Heatmaps showing the output of the clustering
(Fig 4A) clearly depict 4 main clusters of binding sites. For this
analysis we did not take into account directionality of transcription
since the reference was the center of the binding sites. Two
mirrored clusters were merged into cluster 4. Average profiles for
each cluster (Fig 4B black lines) underpinned the distribution of the
marks and their overall signal densities in each cluster. The 50th
and 90th percentile of the distributions are also represented as a
dark and light shadow respectively. Genomic distribution for each
group was calculated (Fig 4C) together with average methylation
levels and CpG density (Fig 4D).
The largest cluster, number 1, is comprised of MBD2 binding
sites with a clear enrichment of DNA methylation and CpG
density but no co-occurrence of any of the epigenetic marks
analyzed. The binding sites are roughly equally distributed over
CGI promoters, exons and intergenic regions (about 20% in each
category). Cluster 2 comprises MBD2 binding sites in CGI located
in exons and introns. Interestingly this group of loci showed high
Figure 2. Genome-wide binding of TTE-MBD2. a) Heatmap displaying tag densities in TTE-MBD2 (left and right) and input (middle) at MBD2
binding sites around 5 kb up- and downstream of the center of the peaks. b) Genomic location of peaks: each category is expressed as fold over
random (y-axis), the random set consists of an equal number of sites having on average same length of the peaks. c) CpG content of each category
expressed as percentage of the total binding sites (y-axis). d) Screenshots from the genome browser showing example of CGI promoters (KDM2A)
and exons (MZF1, ZNF837, ZNF497) binding.
doi:10.1371/journal.pone.0099603.g002
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levels of H3K36me3 and DNA methylation level was high up- and
downstream the binding sites, probably reflecting gene body
methylation pattern [30,31].
Cluster 3 is a small cluster slightly enriched for CGI exons.
Average methylation levels showed an asymmetric pattern, probably
consistent with increased methylation at one flank of the binding sites.
Interestingly, cluster 4 showed strong localized enrichment of
marks associated to active transcription such as H3K4me3, Pol2,
H3K27ac, H2A.Zac and low but appreciable levels of H3K36me3
as well as enrichment for P300. Interestingly, the enriched signals
are positioned at one side of the MBD2 binding sites rather than
coinciding with MBD2. Although cluster 4 represented a small
subset of the total binding sites (1142/8349) it was interesting to
find MBD2 co-occurring with active marks, in line with recent
findings underlining that a fraction of MBD2 binding can mark
also active promoters [23,32]. No enrichment was detected to co-
occur with the histone marks H3K27me3 and H3K9me3, which
are associated with transcriptional repression. The binding sites in
cluster 4 were enriched for CGIs at transcription start sites (TSS-
CGI) (420/1142). CpG density and methylation levels were also
increased at these binding sites.
Representative examples from each cluster are shown (Fig S3):
respectively the CGI promoters of FG2 (cluster 1) and ADHFE1
(cluster 2) and the CGI exons of KLF4 (cluster 3) and KCND3
(cluster 4).
MBD2 binding downstream of active promoters affects
RNA Pol2 distribution
The specific pattern of histone marks and Pol2 binding observed
in cluster 4 showed that MBD2 binds close to transcriptional start
sites. Intriguingly, both the epigenetic marks and Pol2 were limited
to a short and discrete genomic stretch that is not consistent with
variable gene length. Our subsequent analysis excluded that we
were dealing with short genes. Moreover MBD2 binding in WT
MCF-7 cells was confirmed for a subset of loci, to exclude possible
artifacts due to the over-expression (Fig S4).
To investigate the binding of MBD2 and its implication for
transcriptional activity, we calculated the average tag density of
the enriched features Pol2, and MBD2 relative to the TSS (Fig 5A)
of the annotated promoters binding sites from cluster 4 (420/
1142), together with CpG and methylation density (Fig 5B). At
these 420 sites, MBD2 binding is located around 1 kb downstream
from the TSS. These promoters are enriched for Pol2 and are
CpG dense. Next, we assessed the expression levels of the genes in
the same cluster. We first ranked all Ref-seq annotated genes from
highest to lowest in terms of RNA transcript levels and divided
them into three bins (hereafter defined as ‘‘high’’, ’’medium’’ and
‘‘low’’). We then compared our subgroup of genes in cluster 4 to
overall expression levels. This analysis showed that the genes in
cluster 4 are indeed expressed at low to medium levels (Fig 5C). A
similar analysis was performed for H3K36me3 levels, ranking
genes in three categories according to their H3K36me3. This
analysis confirmed that genes downstream of the promoters in
cluster 4 were active and displayed H3K36me3 levels nearly
reaching that of medium expressed genes (Fig S5).
Given the gene expression levels and ChIP data, MBD2 binding
sites of cluster 4 may prevent full transcriptional activation i.e.
poises these promoters. Alternatively, MBD2 binding downstream
of the main peak might block elongation of Pol2. Therefore we
performed ChIP-seq for both WT and TTE-MBD2 cells with an
Figure 3. Methylation state at MBD2 binding sites. a) Boxplot displaying methylation level at TTE-MBD2 binding sites compared to random
(0 = 0% methylation, 1 = 100% methylation). b) Genome wide correlation between TTE-MBD2 enrichment (green) and methylation density, calculated
at 1 kb windows ranked by methylation density (dashed line). c) Screenshots from genome browser showing correlation between CpG methylation
density (red track) and TTE-MBD2 peaks at KCNN2, ZNF316, and ASCL5.
doi:10.1371/journal.pone.0099603.g003
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Figure 4. A subset of MBD2 binding sites associate with promoters enriched for active marks. a) Heatmap of signal density using k-
means clustering on TTE-MBD2 peaks (5 kb up/downstream the center of MBD2 peaks) for TTE-MBD2, input, Pol2, H2A.Zac, H3K4me3, H3K27ac,
H3K36me3, P300. The clustering shows four different groups of binding sites (numbers indicated on the right). H3K27me3 H3K9me3 and mCpG levels
are not participating to the clustering itself but average signal density is calculated according to the clustering order. b) Average profiles for each
clusters of the indicated histone marks/transcription factors 5 kb up and downstream the middle of each binding site, windows were divided in
20 bp bin. The mean enrichment is shown using a black line and the 50th and 90th percentile are also displayed using a dark and light color
respectively. c) Genomic location of binding sites within each cluster was calculated as for Figure 2C. d) Average methylation (black line) and average
CpG density (red line) for all binding sites in each cluster, 5 kb up- and downstream the center of the peaks in 100 bp window.
doi:10.1371/journal.pone.0099603.g004
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antibody against the N-term of Pol2 (N-20) to determine Pol2
occupancy independently of the phosphorylation status of its C-
terminal domain (CTD). At the TSS from cluster 4, Pol2
occupancy was slightly higher in the TTE-MBD2 as compared
to the parental MCF-7 cells (fig 5D), which was supported by
increased Pol2 using the CTD antibody (Fig S6). To study whether
this phenomenon is in line with pausing, we determined Pol2
distribution during initiation and elongation by performing Pol2
ChIP-seq in TTE-MBD2 and WT MCF-7 cells with antibodies
specific for phosphorylation at Ser5 (initiation) and Ser2 (elonga-
tion) of the CTD [33]. If MBD2 binding affects pausing, the level
of Ser5 at the promoter should be higher in TTE-MBD2 as
compared to parental MCF-7 cells, instead we found the opposite
(Fig 5E). Confusingly, we observed a decrease of the elongating
Pol2 over gene bodies in the TTE-MBD2 that would be in line
with pausing (Fig 5F). These results are consistent with the idea
that MBD2 might induce a block in Pol2 elongation at these
promoters.
To shed light on these seemingly contradictory results, we
investigated whether the sequence composition in cluster 4
Figure 5. MBD2 and Pol2 distribution at active promoters from cluster 4. a) Average profile of Pol2 (MCF-7 WT) and MBD2 (TTE-MBD2) at
promoters from cluster 4, calculated 5 kb up- and downstream the TSS. Average profile of CpG density, MBD2 and methylation levels at promoters
from cluster 4, calculated 5 kb up- and downstream the TSS. c) Boxplots showing RPKM values for all Ref-seq annotated expressed genes sorted and
divided in 3 categories according to their transcript level, compared to RPKM values for genes annotated from cluster 4. d) Average profile of N-term
Pol2 at promoters from cluster 4, calculated 5 kb up- and downstream the TSS for TTE-MBD2 and WT MCF-7. e) As for 5D average profiles of Ser5
phosphorylated Pol2 at promoters from cluster 4, calculated 5 kb up- and downstream the TSS for TTE-MBD2 and WT MCF-7. f) Average profiles of
Ser2 phosphorylated Pol2 over gene bodies downstream promoters from cluster 4, calculated 2 kb up- and downstream the TSS and the TES, for TTE-
MBD2 and WT MCF-7.
doi:10.1371/journal.pone.0099603.g005
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promoters and downstream regions may provide an explanation.
It has recently been shown that CpG and methylation density in
gene bodies has a modest negative correlation with elongation rate
[34,35]. We therefore determined mCpG density over all genes,
grouped them as previously into three classes (Fig S7 ‘‘high’’,
‘‘medium’’ and ‘‘low’’) and compared them with genes in cluster 4.
The CpG density of cluster 4 genes over gene bodies was in the
same range as those in the high CpG bin which was supported by
the DNA methylation distribution (Fig S8).
Note that in MCF-7 WT, that is in the absence of
(over)expression of MBD2, this class of promoters are already
decorated with active marks (Fig 4A) and transcribed at low levels
(Fig 5C) which may in part be due to their sequence composition
and methylation density over the gene-body. As the binding of
MBD2 in TTE-MBD2 cells did not change the level of
transcription (data not shown), the epigenetic and transcription
state of these genes are apparently not affected by MBD2 binding.
MBD2 binds hyper-methylated hallmarks of cancer
Most of the MBD2 binding sites in the MCF-7 breast cancer cell
line were located at highly methylated promoters and exonic CpG
islands that are rarely methylated in normal tissues. To investigate
whether the observed MBD2 binding patterns could be a feature
of breast cancers, we first checked the methylation status of all
MBD2 bound regions in the HMEC cell line, a model of non-
cancer human mammary epithelial cells [36]. In HMEC,
methylation at regions bound by MBD2 (in TTE-MBD2 MCF-
7) showed a very broad methylation range from 10 to 90% similar
to a random distribution (Fig 6A) even though the global
methylation level in HMEC is higher than in MCF-7 (Fig 6B).
The specific methylation increase at CpG rich sites MBD2 sites
and the global decrease compared to normal breast tissue is in line
with reported aberrations in cancer methylome: a global hypo-
methylation and local hypermethylation [37].
This prompted the question whether in primary cancers
hypermethylation occurred at MBD2 binding sites as in MCF-7.
Therefore, we calculated the methylation status at MBD2 binding
sites in a large cohort of primary breast cancers (from TCGA:
breast invasive carcinoma methylation data). We computed for
each cancer sample as well as for a set of samples from healthy
individuals included in this TCGA study the mean methylation
levels at all MBD2 binding sites. The same analysis was performed
for an equal number of random sites corrected for genomic
distribution (as for Fig 3A). Interestingly, most of the tumor
samples showed increased mean methylation at all MBD2 binding
sites as compared to normal samples (Fig 6C), whereas increased
methylation was not observed at random sites.
We extended our analysis to MBD2 regions in cluster 4,
comparing mean methylation levels at binding sites from this
specific group between tumor and normal to mean methylation at
all MBD2 sites (Fig 6D). Also in this case we observed a statistically
relevant increase in methylation in the tumor versus normal at
genomic location from cluster 4 (Mann-Whitney U p-value ,
2.2e216).
The relevance of increases DNA methylation at MBD2 binding
sites for the etiology of primary breast cancer remains to be
elucidated. Our findings indicate that MBD2 is likely to bind to
the MBD2 sites locations in primary cancer and may contribute to
the regulation of transcription of the set of genes.
Concluding Remarks
Taken together our data suggest that MBD2 binds primarily at
highly methylated regions, with a strong preference for CpG
islands overlapping promoters. A small subset of promoters bound
by MBD2 at a position downstream of the transcription start site
(within 1 kb) is enriched for active marks and Pol2, and that these
genes are expressed at low levels. We show that binding of MBD2
alters the Pol2 distribution: increase of Pol2 (phosphorylation
independent), reduction of P-Ser5 at the region immediately
downstream of the promoter and decrease of P-Ser2 in the
remainder of the gene body. Our analysis also highlights that
MBD2 binding sites display increased methylation in primary
breast cancer tissues as compared to normal samples or mammary
epithelial cells. This suggests that MBD2 may bind at these loci in
breast cancer instigated by increased methylation. Analysis of
MBD2 binding in cancer cells will be needed to determine its
consequence on transcription and contribution to the etiology or
maintenance of breast cancer.
Materials and Methods
Cloning and stable cell lines
The pTTE retroviral vector was obtained as previously
described [38].
Full length MBD2 was PCR amplified from human MBD2
plasmid (image clone collection) and then cloned using EcoR1 and
Xhol site to create pTTE-MBD2.
MCF-7 cells where transfected with the pTTE-MBD2 construct
and single clones where selected with 1 mg/ml of puromycin. Cells
were maintained in Dulbecco’s modified Eagle’s medium supple-
mented with 10% fetal calf serum, 100 ml/ml Penicillin and 100
units/ml Streptomycin and 1 mg/ml puromycin at 37uC in 5%
CO2.
Antibodies and western blot
Rabbit anti-MBD2 Antibody, Bethyl Laboratories, (A301-632),
GAPDH (ab8245-100) and BB2 (against TY1 epitope) were used
for Western Blot analysis. The same MBD2 and BB2 together with
H2A.Zac (acetyl K4+K7+K11, ab18262, sheep polyclonal,
659355) from Abcam, Pol2 (8WG16 Monoclonal Antibody,
Catalog Number MMS-126R, Covance), H3K4me3 from Diag-
enode (pAb-MEHAHS-024, rabbit polyclonal, HC-0010), Ser5
Pol2 (phospho-CTD Ser-5, clone 3E8, Millipore Cat 04-1572) and
Ser2 (phospho CTD Ser-2, clone 3E10, Millipore Cat 04-1571),
N-term Pol2 (Pol II N-20 sc-899X SantaCruz) were used for ChIP-
seq, Western blot analysis was performed according to standard
procedure on whole cell lysates.
Nuclear protein extraction and mass spec analysis
Nuclear extracts from TTE-MBD2 and WT MCF-7 were
prepared as previously described [39]. For the immunoprecipita-
tion 500 mg of nuclear proteins were incubated over night at 4uC
with 50 ml protein A/G plus-agarose beads and 5 mg BB2
antibody, each sample was prepared in triplicates. After washes
samples were subjected to on-bead trypsin digestion as previously
described [40] and prepared for mass spec analysis. Peptides were
eluted from stage-tips with 2620 ul of 60% acetonitrile/0.1%
formic acid. Acetonitrile was evaporated using a speed vacuum
centrifuge and the sample volume was brought to 15 ul adding
0.1% formic acid. 5 ul of peptide solution was loaded on a fused
silica column (75 um inner diameter, 30 cm length) (Next
Advanced) packed in-house with ReproSil-Pur C18-AQ 1.8 mm
resin (Dr. Maisch) using a EASY-nLC II (Thermo Scientific).
Peptides were eluted over 120 minutes using a segmented gradient
with increasing concentration of acetonitrile. The column was kept
at a temperature of 50uC using a column oven (Sonation). Eluting
peptides were sprayed directly into a QExactive mass spectrometer
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(Thermo Scientific). The mass spectrometer was operated in data
dependent TOP10 sequencing mode. Target values for full MS
scans were set to 3.000.000 and for MS/MS to 100.000 with
maximum fill times of 20 ms and 120 ms, respectively. MS spectra
were recorded at a resolution (m/z= 400) of 70.000 and MS/MS
spectra at a resolution of 17.500. Peptides were fragmented using
higher energy collision induced dissociation (HCD) with
NCE=25. The isolation window was set to 3 Th. Singly charged
peaks or peaks with charge state were excluded for sequencing.
Dynamic exclusion was activated and the window was set to 20 s.
Data acquisition was performed using Xcalibur software. Data
analysis was performed basically as described in [26] using the
MaxQuant software package [41]. Statistical analysis was
performed using Perseus and the interaction data was visualized
using R.
Double step-crosslinking and chromatin-
immunoprecipitation
Tagged-MBD2 ChIPs were performed with MBD2 Ab (A301-
632) and BB2 (against Ty1) following a double step crosslinking
method [42].
Cells were trypsinized and re-suspended with PBS to a final
concentration of 86106 cells/500 ml PBS. Cell suspensions were
crosslinked with 1.5 mM DSG (disuccinimidyl glutarate, Thermo,
#20593) for 459 at room temperature with gentle rotation. After
two washes with 500 ml PBS, cell pellets were re-suspended in 1 ml
PBS and 1% formaldehyde was added for 109 at room
temperature.
Cross-linking was quenched with 125 mM glycine and after two
times ice-cold PBS washes, pellets were resuspended in 270 ml lysis
Figure 6. Methylation levels of MBD2 binding sites in normal and breast cancer. a) Boxplot displaying methylation levels at TTE-MBD2
binding sites in MCF-7 and HMEC compared to methylation at random regions respectively in MCF-7 and HMEC. Random is corrected for genomic
distribution as for Fig 3A. b) Genome-wide methylation levels in MCF-7 and HMEC calculated in 50 bp sliding windows. c) Dot-plot showing mean
methylation for each samples (#patients on X-axis) at all MBD2 binding sites: red dots are indicating mean-methylation at MBD2 sites in tumor
samples (MBD2_tumor) and green for healthy samples (MBD2_normal). Same analysis at a random set of sites (as for Fig 3A) for the two datasets is
depicted in grey. On the y-axis methylation levels (0 = 0% methylation, 1 = 100% methylation). d) As for Fig 6C dot-plot showing mean methylation
for each samples (#patients on X-axis) at all MBD2 binding sites and at the subset represented in cluster 4.
doi:10.1371/journal.pone.0099603.g006
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buffer (50 mM Tris pH 8.0, 1%SDS, 10 mMEDTA protease
inhibitor) and incubated 59 on ice.
Sonication was performed for 159–209 with Bioruptor sonicator
(NGS, Diagenode) and lysates were centrifuged at 13000 rpm
4uC, for 5 min.
20 ml of Dynabeads protein A/G (Life Technologies) and 50 ml
of Dynabeads protein G were pre-incubated for 1 h respectively
with 4 ml MBD2 and 5 mg of BB2, in 1 ml IP buffer
(0.01%SDS,1.1% TritonX100, 1.2 mM EDTA, 16.7 mM Tris
pH 8.0, 167 mM NaCl) by gentle rocking at 4uC.
After 1 ml wash with IP buffer, antibody-loaded beads were
incubated with 100 ml chromatin, 100 ml of 50 mg/ml BSA in IP
buffer, 800 ml IP buffer and 1.25 ml 10 mg/ml yeast tRNA
(Ambion #AM7119) over-night at 4uC.
Beads were washed subsequently with 5 different buffers: one
time with IP buffers, two times with RIPA buffer (25 mM TrisHCl
pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate,
0.1% SDS), two times with RIPA high salt buffer (1:10 mixture
with 5 M NaCl), one time with LiCl wash buffer (2 mM EDTA,
20 mM Tris pH 8, 250 mM LiCl, 1% NP-40, 1% sodium
deoxycholate) and two times with TE buffer.
Beads were resuspended in 50 ml freshly prepared elution buffer
(1%SDS, 0.1 M NaHCO3) supplemented with 5 mM DTT and
incubated for 459 at 65uC in a thermomixer.
Supernatants were collected and beads were re-suspended once
more with 50 ml fresh elution buffer, the two supernatants were
joined, supplemented with 300 mM NaCl 0.5 ml RNase cocktail
and de-crosslinked for 4 hours at 65uC, shaking.
After addition of 2 ml 1 M Tris pH 6.8 and 2 ml 20 mg/mL
proteinase K samples were incubated at 65uC for 1 more hour.
DNA was purified with QIAGEN columns, and 2–5 mg were
used for library preparation and sequencing. 50 ml from TTE-
MBD2 chromatin was also de-crosslinked and prepared for
sequencing (referred as input chromatin).
For all the other chromatin-immunoprecipitations cells were
fixed for 10 minutes at room temperature by the addition of
formaldehyde to a final concentration of 1%, after which glycine
was added to a concentration of 100 mM. Cells were then washed
twice with PBS and collected into lysis buffer (150 mM NaCl,
20 mM Tris pH 8.0, 2 mM EDTA, 1% triton X-100, protease
inhibitor [complete EDTA free, Roche, 04 693 132 001], 100 mM
PMSF). The lysate was sonicated to an average of 300–500 bp
fragments. The resulting sonicate was centrifuged at 40006g for 5
minutes, an aliquot of 10% retained for input and the remaining
material transferred to a fresh tube. 20 ml protein G or protein A/
G magnetic beads were pre-incubated with the different antibodies
for 4 hours and after washing away the excess of antibody,
chromatin was added O.N at 4uC.
Afterwards, the complexes were washed, then reverse cross-
linked for a minimum of 4 hours at 65uC. Recovered DNA was
then purified using a Qiaquick spin column and eluted in 50 of
10 mM Tris pH 8.0.
Strand specific RNA (ssRNA) preparation was performed as
previously described [43].
Illumina high-throughput sequencing and data analysis
Libraries were prepared according to manufacturer’s standards.
Briefly 5–10 ng DNA was subjected to end repair using Klenow
DNA polymerase, T4 ligase and T4 polynucleotide kinase (T4
PNK). A 39 protruding A base was generated using Taq
polymerase and Illumina adapters (GAIIX) or NEXTflex adapters
(HiSeq2000) were ligated. The DNA was loaded on E-gel for size
selection (300 bp), further amplified by PCR and used for cluster
generation on the Illumina GAIIx or HiSeq2000 genome
analyzer. The 36 (GAIIx) or 43 bp tags (HiSeq2000) were mapped
to the reference human genome hg19 (NCBI build 37), using the
BWA allowing one mismatch. Only uniquely mapped-reads were
used for data analysis and visualization.
Peak-calling was performed with MACS 2.0 tool against a
reference input sample from the same cell line (TTE-MBD2).
Genomic distribution of peaks or random regions was performed
with a script that annotates binding sites according to all RefSeq
genes, taking into account 4 functional categories: promoters (1 kb
up or downstream the TSS), exons, introns and intergenic. The
random set consists of an equal number of sites having on average
same length of the peaks. Each category is subsequently grouped
in ‘‘CGI’’ or ‘‘non-CGI’’ according to the overlap with CpG
islands. The assignment is non-overlapping, peaks are only
assigned to a category once and the above order is hierarchical.
Whole genome bisulfite sequencing data were analyzed as
previously described [29].
Cytosine methylation levels within CpG context are present in
the MCF-7_CpG_methcounts.bed.gz file and are used to calculate
methylation levels (between 0= 0% methylation and 1= 100%
methylation) and mCpG density per 1 kb genomic window.
Heatmaps and k-mean clustering together with relative average
profiles (Fig 4B) were performed using a Python package available
at http://simonvh.github.io/fluff/. ChIP-seq datasets used for
generating average profiles and comparisons between WT and
TTE-MBD2 were normalized for total number of uniquely
mapped-reads. All average profiles are obtained counting tags
(or methylated CpG) per 100 bp windows.
For gene expression analysis RPKM values were calculated
from RNA-seq data and only expressed genes were taken into
account. For H3K36me3 levels the number of tags per bp were
computed over the gene bodies on all Ref-seq annotated genes.
For Ser2-P average profiles over gene bodies downstream
promoters from cluster 4 only genes longer than 4 kb were taken
into account. Same criteria were followed to compute mCpG
density (Fig S7–S8).
R was used to generate most of the graphs.
The data generated for this work have been deposited in
NCBI’s Gene Expression Omnibus and are accessible through
GEO Series accession number GSE54693.
The rest of the ChIP-Seq datasets (H3K27ac; H3K36me3;
P300; H3K27me3; H3K9me3) were retrieved from the ENCODE
data repository site (http://genome.ucsc.edu/ENCODE/).
Supporting Information
Figure S1 ChIP qPCR for MBD2 ChIP on WT, TTE-MBD2
and Ty1 ChIP on TTE-MBD2 at some representative binding
sites. The y-axis shows recoveries expressed as % of input.
(TIF)
Figure S2 Heatmap displaying tag densities in 2 MBD2 ChIP-
seq replica on TTE-MBD2, Ty1 ChIP on TTE-MBD2 (‘‘Ty1’’)
and WT (‘‘Ty1 control’’) and input at TTE-MBD2 binding sites
around 5 kb up and downstream the center of the peaks.
(TIF)
Figure S3 Screenshots from the genome browser with examples
from each cluster.
(TIF)
Figure S4 ChIP qPCR for MBD2 ChIP on WT and TTE-
MBD2 tested at 1 kb downstream of a set of loci from cluster 4.
(TIF)
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Figure S5 As for Fig 5C boxplots showing H3K36me3 tag
densities for all Ref-seq annotated genes sorted and divided in 3
categories according to H3K36me3 levels, compared to
H3K36me3 density for genes downstream annotated promoters
in cluster 4.
(TIF)
Figure S6 Average profiles of Pol2 (using the antibody against
CTD, 8WG16) at promoters from cluster 4, calculated 5 kb up-
and downstream the TSS for TTE-MBD2 and WT MCF-7.
(TIF)
Figure S7 Boxplots showing mCpG densities for all Ref-seq
annotated genes sorted and divided in 3 categories according to
mCpG density, compared to density in genes downstream
promoters from cluster 4.
(TIF)
Figure S8 Average methylation levels calculated 2 kb up- and
downstream the TSS and the TES, for gene bodies downstream
promoters from cluster 4 (as Fig 5F), and for the ‘‘high’’ bin (Fig
S7) with highest mCpG density.
(TIF)
Table S1 Complete list of all identified proteins after Ty1
immunoprecipitation on both TTE-MBD2 and WT cells followed
by mass spectrometry analysis. Results from triplicate pull-downs
were analyzed with MaxQuant and label-free quantitation (LFQ).
(XLSX)
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